Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 4601 - 4625 of 5297 in total

RGX-121

RGX-121 is designed to use the NAV AAV9 vector to deliver the human iduronate-2-sulfatase gene to the central nervous system.
Investigational

VO659

VO659 is an antisense oligonucleotide being investigated for the treatment of Huntington's disease.
Investigational

Tuvusertib

Investigational

(R)-Gossypol

(R)-Gossypol is the R-isomer of Gossypol.
Investigational

SY-5609

Investigational

Dazodalibep

Dazodalibep is under investigation in clinical trial NCT06104124 (A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity).
Investigational

3,5-Dihydro-5-Methylidene-4h-Imidazol-4-On

Experimental

4'-nitrophenyl-3i-thiolaminaritrioside

Experimental

3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL

Experimental

Obexelimab

Obexelimab is under investigation in clinical trial NCT02725515 (A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus).
Investigational

Retlirafusp alfa

Investigational

N,N-Bis(3-(D-gluconamido)propyl)deoxycholamide

Experimental

Botaretigene sparoparvovec

Investigational

2-amino-3-(4-amino-1H-indol-3-yl)propanoic acid

Experimental

TETRAHEDRAL INTERMEDIATE OF BLASTICIDIN S

Experimental

3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole

Experimental

N-[2-(1h-Indol-5-Yl)-Butyl]-4-Sulfamoyl-Benzamide

Experimental

3,4-Methylenedioxy-N-isopropylamphetamine

MDI-P has demonstrated potent anti-HIV activity. MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF").
Investigational

3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE

Experimental

1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone

Experimental

Vonlerolizumab

Vonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy).
Investigational

Xaluritamig

Xaluritamig is a novel humanized bispecific T cell recruiting antibody cross-reactive to human and nonhuman primate STEAP1 and CD3.
Investigational

N-(3-Cyclopropyl(5,6,7,8,9,10-Hexahydro-2-Oxo-2h-Cycloocta[B]Pyran-3-Yl)Methyl)Phenylbenzensulfonamide

Experimental

Miransertib

Miransertib is under investigation in clinical trial NCT01473095 (Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma).
Investigational

Boserolimab

Investigational
Displaying drugs 4601 - 4625 of 5297 in total